Published in Pharma Investments, Ventures and Law Weekly, March 5th, 2006
Commenting on the second quarter results, Michael J. Valentino noted, "I am certainly very pleased with our solid quarterly performance, mainly driven by the early strength of the cough/cold season, strong consumer demand and further market penetration of our Mucinex franchise. During the quarter, we carried a significant product backorder and it was not until mid-December when finished product made from our second guaifenesin supplier, Delta Synthetic Co., Ltd., could be shipped to customers."
Valentino added, "Despite the fact...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly